Key Highlights
- Carisma Therapeutics appoints Marella Thorell and David Scadden, M.D., to its Board.
- Effective Date: June 30, 2024.
- Regina Hodits and Björn Odlander to step down from the Board on June 30, 2024.
- Expertise: Enhances Carisma’s capabilities in immunotherapy development.
- Company Focus: Innovative cell therapy platform for cancer treatment.
Source: PR Newswire
Notable Quotes
- “We are pleased to welcome David and Marella to the Carisma Board of Directors. Their vast experience in the life sciences sector will be instrumental in advancing our cell therapy platform focused on engineered macrophages.” — Sanford Zweifach, Chair of the Board of Directors at Carisma
- “Dr. Scadden’s renowned expertise as a physician and medical researcher will be incredibly valuable to Carisma, and we are honored to welcome him to our Board of Directors. Ms. Thorell’s experience as a public company executive and Board Member of biotech companies will enhance the business capabilities of our Board.” — Steven Kelly, President and CEO at Carisma
SoHC's Take
The recent appointments of Marella Thorell and David Scadden, M.D., to the Board of Directors of Carisma Therapeutics mark a significant enhancement in the company’s leadership team. With their extensive backgrounds in finance, operations, and regenerative medicine, Thorell and Scadden bring a wealth of knowledge that will be pivotal in driving Carisma’s innovative cell therapy platform. As the company aims to advance its immunotherapy solutions, the expertise of these new board members will provide critical insights and strategic direction, bolstering Carisma’s mission to develop transformative treatments for cancer and other serious diseases. The departure of Regina Hodits and Björn Odlander, acknowledged for their substantial contributions, also highlights the dynamic evolution within Carisma, positioning it for continued growth and innovation in the biotech industry.
